Loss of function mutations in the neurofibromatosis Type 2 (NF2) gene, coding for a tumour suppressor, Merlin, cause multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas. These tumours may occur sporadically or as part of the hereditary condition neurofibromatosis Type 2 (NF2). Current treatment is confined to (radio) surgery and no targeted drug therapies exist. NF2 mutations and/or Merlin inactivation are also seen in other cancers including some mesothelioma, breast cancer, colorectal carcinoma, melanoma and glioblastoma. To study the relationship between Merlin deficiency and tumourigenesis, we have developed an in vitro model comprising human primary schwannoma cells, the most common Merlindeficient tumour and the hallmark for NF2. Using this model, we show increased expression of cellular prion protein (PrP C ) in schwannoma cells and tissues. In addition, a strong overexpression of PrP C is observed in human Merlin-deficient mesothelioma cell line TRA and in human Merlin-deficient meningiomas. PrP C contributes to increased proliferation, cell-matrix adhesion and survival in schwannoma cells acting via 37/67 kDa non-integrin laminin receptor (LR/37/67 kDa) and downstream ERK1/2, PI3K/AKT and FAK signalling pathways. PrP C protein is also strongly released from schwannoma cells via exosomes and as a free peptide suggesting that it may act in an autocrine and/or paracrine manner. We suggest that PrP C and its interactor, LR/37/67 kDa, could be potential therapeutic targets for schwannomas and other Merlin-deficient tumours.
INTRODUCTION
Mutations in a gene coding for the tumour suppressor protein Merlin (NF2), lead to the development of multiple tumours of the nervous system including schwannomas, meningiomas and ependymomas. These tumours occur sporadically or as a part of the hereditary disease Neurofibromatosis type 2 (NF2).
1
NF2 gene mutations/Merlin inactivation are also found in a proportion of breast cancer, colorectal carcinoma, melanoma, glioblastoma and mesothelioma. 2 Current treatments for NF2, surgery and radiosurgery, are carrying risks and cannot be used in all patients; therefore, new drug-based treatments are needed. 3 Schwannoma is the most common Merlin-deficient tumour and the hallmark for NF2. 4 Using a primary human schwannoma in vitro cell model, we have previously uncovered signalling pathways involved in schwannoma development including; ERK1/2, FAK, Src, NFκB, JNK, PI3K/AKT, p53/MDM2 and the ubiquitin ligase CRL4 DCAF1 . [5] [6] [7] [8] A cDNA array hybridisation and RT-PCR highlighted significantly increased activity of the prion protein (PrP)-encoding gene, PRNP, in schwannoma compared to Schwann cells. 9 Cellular prion protein PrP C is an N-glycosylated protein, tethered to the cell membrane via a C-terminal glycosyl-phosphatidylinositol (GPI) anchor. 10 PrP C is expressed in CNS neurons and glial cells 10 as well as in PNS axons and associated Schwann cells, 11 displaying important biological functions such as myelination maintenance, neural precursor proliferation and adult neurogenesis.
12-14 PrP C is overexpressed in different cancers including colorectal cancer, breast cancer, pancreatic cancer and melanoma, regulating proliferation, cell adhesion and survival 15 via key signalling pathways (cyclin D1, ERK1/2, caspase-3 and PI3K/AKT), 16, 17 previously shown to be involved in schwannoma development. 18, 19 PrP C can be released from cells, taking part in autocrine and/or paracrine signalling. 20, 21 PrP C has been shown to bind to the cell surface 37/67 kDa-laminin receptor protein (LR/ 37/67 kDa), which could be potentially targeted by anti-LR 37/67 kDa antibodies 22 and LR/37/67 kDa/laminin interaction inhibitor NSC47924. 23 We demonstrate for the first time that (a) PrP C protein is strongly overexpressed in schwannoma compared with the control Schwann cells/tissues; (b) that this overexpression is negatively regulated by Merlin and depends on NFκB; (c) PrP C levels are also highly increased in Merlin-deficient human mesothelioma cell line TRA and Merlin-deficient human meningioma grade I tissues and primary cells; (d) PrP C increases schwannoma cell proliferation, survival and cell-matrix adhesion acting via LR/37/67 kDa and downstream ERK1/2, PI3K/AKT and FAK signalling pathways; (e) PrP C is released from schwannoma cells, both via exosomes and also as cleaved peptides. We therefore suggest that decreasing PrP C levels either by using humanised anti-PrP antibody PRN100 (clinical trials are planned by MRC Prion Unit for sporadic Creutzfeldt-Jakob disease 24 ); or proteasome inhibitor (targeting NFκB) Bortezomib (FDA approved for multiple myeloma 25 ); or targeting PrP C receptor and/or the, LR/ 37/67 kDa-laminin receptor, using inhibitors such as NSC47924 or antibodies 22 could be a good therapeutic strategy for schwannoma and other Merlin-deficient tumours.
RESULTS

Cellular di-glycosylated form or prion protein PrP
C is strongly overexpressed in schwannoma Immunocytochemistry shows increased PrP staining in Merlinnegative human primary schwannoma cells (NF2 − / − ), throughout the cytoplasm and cell membranes (Figure 1a To define which form of the PrP is overexpressed in schwannoma (that is, either the normal cellular PrP C , or pathogenic infectious proteinase K-resistant PrP Res ), cells were either lysed normally with the addition of protease inhibitors or with proteinase K. 16 Western blot analysis of schwannoma lysates treated with proteinase K show complete ablation of PrP (Figure 1d , right lane) compared to control (Figure 1d , left lane) suggesting that the cells express cellular PrP C and not PrP Res . Mature, di-glycosylated PrP C has been linked to resistance to apoptosis in several cancers, whereas lack of glycosylation is linked to PrP C to PrP Res conversion. 26 Using a PNGaseF deglycosylation assay, we show that the PrP C expressed in both Schwann and schwannoma cells is di-glycosylated (Figure 1e , left 
PrP
C overexpression is due to increased transcription and translation and not due to decreased proteosomal degradation Treatment of schwannoma cells with transcription inhibitor actinomycin D (ActD) (10 nM, 24h) ( Figure 1f ) and translation inhibitor cycloheximide (CHX) (1 μM, 24 h) reduced PrP C levels bỹ 80% (Figure 1g ). In addition, proteosomal degradation inhibitor MG132 (1 μM, 24 h) increased PrP C level by~50% (Figure 1h ). These and our previous data on PRNP gene activation in schwannoma, 9 suggest that increased PrP C level is due to increased transcription and translation, and not due to intracellular accumulation caused by decreased proteosomal degradation. 27 Similarly to schwannoma, PrP C is also upregulated in human Merlin-deficient mesothelioma cell line TRA 28 ( Figure 1i Merlin reintroduction is sufficient to reduce PrP C levels in Merlindeficient schwannoma and mesothelioma but not meningioma cells To investigate whether PrP C overexpression is due to Merlin deficiency, we reintroduced wild-type Merlin (NF2) gene into schwannoma, TRA and meningioma grade I cells, using recombinant adenovirus AdNF2. 29 Interestingly, Merlin reintroduction reduced PrP C levels in both schwannoma ( Figure 2a ) and TRA ( Figure 2b ) cells but not in meningioma cells (Figure 2c ), suggesting that, in Merlin-negative meningioma, additional mutations may be involved in the regulation of PrP C . [30] [31] [32] [33] [34] PrP C expression in schwannoma cells is upregulated by NFκB
To find potential therapeutic targets downstream of Merlin that are involved in increased levels of PrP C , we inhibited two major transcription regulators in schwannoma, ubiquitin E3 ligase CRL4 (DCAF1) using shRNA 35, 36 and NFκB using SN50 inhibitor (8 μg/ml, 72 h). 5 We demonstrate that PrP C overexpression in schwannoma cells was not affected by CRL4 DCAF1 shRNA (Figure 2d ), but instead, was significantly decreased upon treatment with NFκB inhibitor SN50 (Figure 2e; Supplementary  Figure 2) . Thus, in schwannoma PrP C overexpression is due to Merlin deficiency and downstream activation of transcription factor NFκB.
C is released mainly via exosomes from schwannoma cells A small but significant increase in PrP C was detected by ELISA in the medium from schwannoma cells compared to Schwann cells ( Figure 3a) . As PrP C can be released via exosomes, 20 we first checked the expression of exosome/late endosome marker CD63 in schwannoma and Schwann cells. Figure 3b demonstrates a strong overexpression of CD63 in schwannoma compared to Schwann cells, suggesting higher levels of exosomes/late endosomes in these cells ( Figure 3b ). Additional ELISA experiments on growth factor medium (GFM) media containing exosome-free FCS show that the majority of PrP C released from schwannoma cells is released via exosomes and only a small portion as free peptides. The levels of exosome-bound PrP C ( Figure 3c , dark grey bar) are six-fold higher compared to the levels of free PrP C ( Figure 3c , black bar) present in the supernatant fraction left over after exosomes were isolated. This was compared to 'whole' cell culture medium, which was simultaneously collected and run ( Figure 3c , medium light grey bar) and fresh GFM was used as a negative control ( Figure 3c , white bar). A similar pattern was demonstrated by western blotting where clear bands for PrP C are seen in the exosome fraction ( Figure 3d , second row). PrP C is a glycoprotein and therefore it's molecular weight spans between 30 and 37 kDa. 10 No band for PrP C is detectable in the supernatant fraction DCAF1 shRNA has no effect on PrP C expression. (e) NFκB inhibitor SN50 significantly decreased PrP C levels. Data are presented as ± s.e.m. (NsP40.05, *Po0.05, **P o0.01).
of medium remaining after exosome isolation collected from schwannoma cells (Figure 3d , third row), which could be due to lower sensitivity of western blot technique compared to ELISA. Furthermore, immunocytochemistry showed co-localisation between PrP C and CD63 in schwannoma cells ( Figure 3e ). The levels of free PrP C are not altered upon treatment of cells with PIPLC (0.2 U/ml, 3 h), which cleaves PrP C at the GPI anchor 37 ( Figure 3f ) and there is no significant difference in the amount of PrP C released into the cell culture medium after PIPLC treatment (Figure 3g ). Thus, free PrP C ( Figure 3c ) is released by other mechanisms than PIPLCmediated cleavage. One alternative mechanism is ADAM10 metalloproteinase-mediated cleavage. 38 We demonstrate that upon schwannoma cell treatment with ADAM10 inhibitor GI254023X (20 μM) for 3 h, the levels of PrP C increased in cell lysates ( Figure 3h ) and decreased in culture media (Figure 3i ), suggesting that in schwannoma cells PrP C cleavage and release is mediated at least partially by ADAM10 metalloproteinase.
Reducing PrP
C levels decreases proliferation and survival of schwannoma cells To investigate functional relevance of PrP C overexpression we used two methods to reduce PrP C expression in schwannoma cells; (1) two sets of PRNP shRNA lentiviral particles; (2) an antiprion agent TCS, both techniques strongly reduced PrP C expression (Supplementary Figure 3ai) . As PRNP shRNA lentiviral particles from Santa Cruz and PRNP shRNA lentivirus from GE Dharmacon (GE Healthcare Life Sciences, Lafayette, CO, USA) displayed similar efficiency for PrP knockdown and the decrease of downstream signalling pathways (Supplementary Figures 3ai and aii) , we combined the data for both shRNA's. We demonstrate that the number of proliferating, Ki67-positive cells and total cell number (DAPI) were significantly reduced upon treatment with PRNP shRNA (Figures 4a and i; Supplementary Figure 4a ) and TCS (Figures 4b and j; Supplementary Figure 4b ), as were levels of proliferation marker, cyclin D1 (Figures 4c and d) . Cells show an increase in apoptosis, detected by cleaved caspase-3 immunolabelling, upon depletion of PrP C using both PRNP shRNA (Figures 4e and i) and TCS (Figures 4f and j) , and confirmed by western blot analysis (Figures 4g and h ). The percentage of alive cells was significantly decreased both using TCS and PRNP shRNA ( Supplementary Figures 4c and d ). We also demonstrate that PrP synthetic peptide (amino acid residues 105-120 of the human prion protein, N terminal) (0.8 μM, 72 h) has a cytoprotective role in schwannoma; rescuing cells from hydrogen peroxide H 2 O 2 C cleavage and release is mediated by ADAM10 metalloproteinase. Cells were treated with ADAM10 inhibitor GI254023X (20 μM) for 3 h and PrP C levels were detected by western blotting in cell lysates (h, n = 5) and by ELISA in culture media (i). E-cadherin is used as a control for ADAM10 inhibition. 70 Phalloidin visualise actin. Data are presented as ± s.e.m. (NsP40.05, *Po 0.05, **P o0.01, ***P o0.001). Multi-track, z-stack confocal microscopy was used for immunofluorescence (d, e).
(500 μM, 12 h)-mediated cell death (Figures 4k-m; Supplementary  Figure 4e ).
C levels decreases cell-matrix adhesion in schwannoma Schwannoma display increased cell-matrix adhesion 39 and PrP C has been shown to affect cell adhesion via interactions with laminin and the neural cell adhesion molecule (NCAM) in hippocampal neurons. 10 Therefore, we investigated whether reducing levels of PrP C would decrease cell adhesion to the laminin/poly-L-lysine cell matrix. After knockdown of PRNP, cells were less capable of adhering to the cell matrix (Figure 4n ). The same reduction in adhesion was also seen upon depletion of PrP C using TCS (Figure 4o) , n = 3. These data suggest that PrP C is involved in the pathological cell-matrix adhesion of schwannoma.
Decreasing expression of PrP C alters activity and expression of several key signalling pathways known to be involved in schwannoma development We next analysed whether signalling via the key pathways (PI3K/ AKT, ERK1/2 and FAK) known to be involved in schwannoma proliferation, survival and cell-matrix adhesion were affected by reducing PrP C . The MAPK pathway has previously been linked to PrP C signalling. C levels significantly increases expression of cleaved caspase-3 using PRNP shRNA, n = 3. (f, j) Reducing PrP C levels using TCS significantly increases expression of (g, h) Both PRNP shRNA (g, n = 5) and TCS (h, n = 5) reduce PrP C levels and significantly increase expression of cleaved caspase-3. (k-m) PrP synthetic peptide (KTNMKHMAGAAAAGAC corresponding to amino acid residues 105-120 of the human prion protein, N terminal) rescues schwannoma cells from H 2 O 2 -mediated cell death. Cells were pre-treated with 0.8 μM of PrP peptide for 72 h followed by addition of H 2 O 2 (500 μM) for additional 12 h (n = 3). Ki67 staining was used to detect proliferating cells (red) (k, l) and cleaved caspase-3 staining (green) for apoptotic cells (k, m). (n, o) Reducing PrP C by shRNA (l, n = 3) and TCS (m, n = 3) reduces cell-matrix adhesion. Data are presented as ± s.e.m. (NsP40.05, *P o0.05, **P o0.01, ***P o0.001). In i, j and k total cell number was monitored by DAPI staining (blue). FAK. Total FAK is significantly reduced after PRNP knockdown and upon treatment with high levels (500 μM) of TCS (Figures 5e and f, dark grey bars). Levels of auto-phosphorylated FAK Y397 are significantly reduced with PRNP shRNA and also at all concentrations of TCS (Figures 5e and f, light grey bars) .
Thus, PrP C is linked to increased expression and activation of ERK1/2, FAK and the activation of PI3K/AKT pathway in schwannoma cells, which are known to be involved in schwannoma development. 18, 19 Treatment with PrP peptide and overexpressing PrP C increases schwann cell proliferation and expression of c-Jun Next, we looked at the effects of increasing PrP C levels in Schwann cells to see whether a pathological phenotype could be induced. First, we used a PrP synthetic peptide to mimic the effect of free PrP in cell culture media. 41, 42 Schwann cells were stimulated for 6 days with 0.8 μM of PrP peptide before looking at levels of proliferation (Ki67) and expression of the proto-oncogene c-Jun, which is involved in Schwann cells proliferation and overexpressed/activated in schwannoma via c-Jun N-terminal kinase (JNK) leading to increased tumour proliferation and survival. 43 Both the number of Ki67-positive cells (Figure 6a , red staining) and c-Jun positive cells (Figure 6b , green staining) increased in cells treated with PrP (105-120) peptide compared to untreated cells in GFM media. Cell morphology, examined by the cytoskeletal F-actin marker phalloidin, showed that Schwann cells looked more like schwannoma tumour cells with an increase in cell spreading and membrane ruffling after treatment with PrP peptide (0.8 μM) for 6 days and 2 weeks compared to untreated cells (Figure 6c ). Cell area was measured using ImageJ software (National Institutes of Health (NIH), Waltham, MA, USA) in n = 52 cells (6 days) and in n = 50 cells (2 weeks) (Figure 6c, right panel) .
Next, we checked whether PrP (105-120) peptide treatment had caused the transformation of endogenous PrP C protein into protease-resistant PrP Res . 44 Cells were lysed either in the presence of protease inhibitors or instead with proteinase K after being treated for 6 days with PrP (105-120) peptide. Results show that cells still expressed normal protease-sensitive PrP C after treated with PrP (105-120) (Figure 6d) .
Moreover, we produced PRNP overexpressing lentiviruses using a pLenti6.2/V5-DEST plasmid (Supplementary Figure 5) , to overexpress full length PrP C in Schwann cells. DNA from PRNP coding region (NCBI Reference Sequence: NG_009087.1) from two separate transformation starter colonies (O/E1B, Figure 6e and Figure 5 . Signalling pathways activated by PrP C in schwannoma. (a, c, e) Reducing levels of PrP C using PRNP shRNA significantly decreased levels of both total (a, dark grey bars, n = 5) and pERK1/2 (a, light grey bar, n = 5), pAKT S473 (c, light grey bars, n = 5) but not total AKT (c, dark grey bars, n = 5) and both total (e, dark grey bars, n = 5) and pFAK Y397 (e, light grey bars, n = 5). (b, d, f) Reducing levels of PrPC using TCS significantly decreased levels of both total (b, dark grey bars, n = 5) and pERK1/2 (b, light grey bar, n = 5), pAKT S473 (d, light grey bars, n = 5) but not total AKT (d, dark grey bars, n = 5) and both total (f dark grey bars, n = 5) and pFAK Y397 (f light grey bars, n = 5). Data are presented as ± s.e. m. (NsP40.05, *Po 0.05, **P o0.01,***P o0.001). PRNP shRNA from both Santa Cruz biotechnologies and GE healthcare were used and the results were merged (Supplementary Figures 3ai and aii) . Figure 6) were used. Western blotting shows that overexpression of PrP C significantly increases levels of both cyclin D1 and c-Jun in Schwann cells compared to the GFPcontaining control (Figures 6e-g; Supplementary Figure 6 ). These data confirm our result obtained using PRNP shRNA and TCS in schwannoma cells indicating the crucial role of PrP C in schwannoma development.
O/E2B, Supplementary
PrP
C employs LR/37/67 kDa to regulate cellular functions Membrane-bound as well as externally added PrP C has been previously shown to interact with the LR/37/67 kDa observed in murine N2a neuroblastoma and hypothalamic neuronal mouse GT1 cell lines. 23 We demonstrate that LR/37/67 kDa is expressed in schwannoma cells (Supplementary Figure 7a) . LR/37/67 kDa co-localises with PrP C in the cytosol, cell membrane and membrane ruffles in permeabilised schwannoma cells (Figure 7a ) and in membrane ruffles of non-permeabalised cells (Figure 7b ). In addition, LR/37/67 kDa interacts with PrP C in schwannoma cell lysates demonstrated by co-immunopreci pitation using both proteins as bait (Figures 7c and d) . Figure 7b) .
DISCUSSION
In the current study we found, that PrP C is overexpressed at the protein level in Merlin-deficient human primary schwannoma cells and tissues compared to controls. Surprisingly, this increase is due to upregulated PRNP transcription and translation per se and not by, as previously reported, decreased proteasomal degradation. 27 We have also revealed that PrP C overexpression translates to other Merlin-deficient tumours, such as human Merlin-negative mesothelioma cell line TRA and human Merlin-negative grade I meningioma cells/tissues. Interestingly, Merlin reintroduction strongly reduced PrP C levels schwannoma and TRA cells but not in meningioma. This could be due to mutations in additional 46 , which require further investigation. We also revealed that PrP C overexpression in schwannoma cells is regulated by transcription factor NFκB, which we previously shown is regulated by Merlin. 6 NFκB has been shown to be involved in PrP-mediated invasion and migration in breast cancer cells 47 and can be activated by PrP peptide PrP(106-126) in human monocytederived dendritic cells. 48 However, its role in the regulation of PrP C expression has never been reported and, importantly, opens a new therapeutic angle. The pathological relevance of PrP C overexpression is emphasised by its increased release from schwannoma cells compared to Schwann cells, which suggest an effect via auto-and/or paracrine mechanisms. 49 Interestingly, PrP C is released both as free (cleaved) peptide, by ADAM10 metalloproteinase cleavage and in association with exosomes. Although, there are previous observations showing exosome-mediated release of PrP C from various cell types such as activated platelets, rat and mouse cortical neurons and mouse neuroblastoma cells, [50] [51] [52] our findings demonstrate this mechanism for the first time in human primary tumour cells.
Concerning the mechanism of action, we have shown that PrP C contributes to the schwannoma development by increasing the expression of the cell cycle regulator cyclin D1 resulting in pathologically enhanced proliferation. Although one study performed on cortical neurons showed no effect of PrP on cyclin D1 levels, 53 most studies agree with our findings. 54 PrP C -deficient fibroblasts displayed a significant downregulation of cyclin D1, 54 and in gastric carcinoma, PrP C accelerated the G1/S phase transition via induction of cyclin D1 through the PI3K/AKT pathway, 55 supporting our finding on the role of PrP C in cyclin D1 expression and AKT activation. We also demonstrate that ERK1/2 activation, which is involved in schwannoma proliferation, 56 is potentiated by PrP C . This is in agreement with other studies reporting the role of MAPK pathway in PrP C -induced neuritogenesis. 53 PrP C in schwannoma cells contributes to increased pathological survival of these cells, which parallels the majority of work in the field. 57 However, a link between PrP C overexpression and increased cell death via caspase-3 has been reported in murine TSM1 neuronal cells and HEK293T cells. 57 Importantly, we found that PrP C has cytoprotective effect in schwannoma, as pre-treatment with PrP (105-120) peptide rescued schwannoma cells from H 2 O 2 oxidative stress-mediated cell death. [62] [63] [64] In summary, we demonstrate that PrP C protein is overexpressed in human schwannoma cells and tissues, and has a part in schwannoma proliferation, cell-matrix adhesion and survival. Importantly, PrP C overexpression was also observed in human mesothelioma cell line TRA and in human grade I meningioma cells and tissues. PrP C is released in schwannoma cells by exosomes and as free peptides, which may contribute to tumourigenesis by autocrine or/and paracrine signalling. PrP C interacts with and acts via LR/37/67 kDa to activate cyclin D1, ERK1/2, PI3K/AKT and FAK in schwannoma cells. Thus, PrP C and LR/37/67 kDa, are good potential therapeutic targets for schwannoma and other Merlin-deficient tumours. PrP C -mediated signalling can be inhibited in two main ways: first, by targeting PrP C directly using humanised anti-PrP antibody PRN100 (MRC Prion Unit for sporadic Creutzfeldt-Jakob disease) 24 or using the proteasome inhibitor (targeting NFκB) Bortezomib (FDA approved for multiple myeloma treatment) (Supplementary information  25 ) ; secondly, by blocking LR/37/67 kDa using inhibitors such as anti-LR/37/67 kDa antibodies, 22 polysulfated glycans, 59 small interfering RNAs 65 and LR/37/67 kDa-Laminin interaction inhibitor NSC47924. 23 
MATERIAL AND METHODS
Cell cultures
After informed consent, schwannoma and meningioma grade I specimens were collected from surgical procedures and normal nerve from postmortem donors. Schwannoma and Schwann cells were cultured in GFM: DMEM; 100 U/ml pen/strep; 2.5 μg/ml Insulin (Thermo Fisher Scientific, Waltham, MA, USA); 0.5 μM Forskolin (Tocris, Bristol, UK); 10% FBS, 2.5 μg/ ml Amphotericin (Sigma, St Louis, MO, USA); 10 nM β1 heregulin; 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Bio-Techne, Minneapolis, MN, USA) at 37°C in 10% CO 2 . 66 Meningioma cells were grown in DMEM containing glucose (4.5 g/l), 10% FBS, 100 U/ml penicillin/streptomycin and 1% glutamine. Human meningeal cells (HMC, Sciencell, San Diego, CA, USA) were grown in the recommended HMC medium (Sciencell) at 37°C and 5% CO 2 . Human mesothelioma cell lines HIB and TRA were cultured in DMEM, containing 10% FBS and 100 U/ml pen/strep at 37°C and 5% CO2. 39 Human schwannoma and meningioma grade I primary cells (passages [1] [2] [3] [4] and tissues used in this study are Merlin-negative (Supplementary Figure 1a; Figure 1k ). All Schwann cell cultures are S100 positive (Supplementary Figure 1b) . The n number states number of biological repeats.
Chemicals
TCS anti-prion agent 13 was from Tocris Bioscience, 67 Proteinase K, MG132, Cycloheximide (CHX), Actinomycin D (Act. D), Phosphatidylinositol Phospholipase C (PIPLC) and DAPI were from Sigma. Synthetic PrP peptide (AA105-120, KTNMKHMAGAAAAGAVVGGLG) was from AbD Serotec (BioRad, Hercules, CA, USA) and mock peptide (NGAKALMGGHGATKVMVGAAA) was kindly provided by Dr M. Salmona of the Instituto Ricerche Farmcologiche Mario Negri, Italy. NFκB inhibitor SN50 was from Calbiochem (La Jolla, CA, USA) and ADAM10 inhibitor GI254023X from Sigma.
Exosome isolation
Cells were cultured for 7 days in medium containing exosome-free FBS (Gibco, Thermo Fisher Scientific). Exosomes were isolated using total exosome isolation reagent (Thermo Fisher Scientific) according to the manufacturer's protocol.
Enzyme-linked immunosorbent assay
Cells were cultured for 3 days in GFM; medium was collected and concentrated 10 × using AmiconUltra filters (Merck Millipore, Billerica, MA, USA). PrP C was detected using Prion Protein (PRNP) ELISA kit (CUSABIO, Hubei, China, ABIN821046) according to the manufacturer's protocol.
Immunocytochemistry
Immunocytochemistry was performed as described in Flaiz et al.
68 using anti-human-PrP C (Santa Cruz Biotechnologies, Dallas, TX, USA), anti-CD63 (Merck Millipore), anti-c-Jun (Cell Signalling Technology, Boston, MA, USA) and anti-LR/37/67 kDa (Novus Biologicals, Littleton, CO, USA) antibodies. Alexa Fluor 488-labelled phalloidin (Life Technologies, Carlsbad, CA, USA) was used to visualise actin filaments (1:100; Molecular Probes, Eugene, OR, USA). Multi-track imaging was performed using a Zeiss Confocal LSM510 (Jena, Germany).
Immunohistochemistry
Tissue sections were pre-treated with EDTA buffer at pH 9 for 30 min, before overnight incubation with the anti-PrP C 12F10 (1:1000; Bioquote, York, UK). Detection was performed with the Vectastain Universal Elite ABC kit (Vector Laboratories, Peterborough, UK).
Proliferation and survival assays
Proliferation and survival assays were carried out using immunofluorescence, after 72 h incubation with viral particles or treatment with TCS prion inhibitor, with anti-Ki67 (Dako, Agilent, Santa Clara, CA, USA) and anticleaved caspase-3 (Cell Signalling Technologies) antibodies. Multi-track imaging was performed using a Zeiss Confocal LSM510.
MTS test
Schwannoma cells were pre-treated with 0.8 μM of PrP peptide for 72 h followed by addition of H 2 O 2 (500 μM) for additional 12 h. MTS test was performed according to manufacturer's protocol (Promega, Madison, WI, USA).
each encoding a different, target-specific 19-25 nt region of PrP C were used to knockdown PRNP expression plus control hairpin shRNA particles. Results were combined with lentivirus made from TRCN0000083488, part of a TRC PRNP shRNA, glycerol set (GE Dharmacon, GE Healthcare Life Sciences). 37/67 kDa-Laminin Receptor shRNA (h) lentiviral particles (Santa Cruz Biotechnologies) were used to knockdown LR/37/67 kDa (h) (pool of three to five expression constructs that encode a 19-25 nt (plus hairpin)).
PRNP overexpressing clone DNA from PRNP coding region (NCBI Reference Sequence: NG_009087.1) from two separate transformation starter colonies (1B and 2B) were cloned into a pLenti6 overexpressing vector (Invitrogen, Carlsbad, CA, USA). Lentiviral particles were produced by transfection into HEK293FT cells using Fugene 6 (Promega).
Co-immunoprecipitation
Primary human schwannoma cells (1 mg) lysed in low-salt buffer was incubated overnight with 1 μg normal IgG (Santa Cruz Biotechnologies) or 1 μg anti-PrP antibody (Sigma), 37/67 kDa anti-laminin receptor (Abcam, Cambridge, MA, USA) in the presence of protein G agarose beads (GE healthcare).
Western blotting
After western blotting 39 membranes were incubated with primary antibodies: anti-PrP, anti-cleaved caspase-3, anti-cyclin D1, anti-total MAPK/ERK1/2, anti-total FAK, anti-pFAK Tyr 
Statistics
Unpaired student's two-tailed t-test was used in all pairwise comparisons and analysis of variance (one-way Anova) followed by post hoc Tukey test for multiple comparisons. F-test was used to compare variances and s.d. between the groups compared to meet the assumption of the statistical test. Experiments were performed in at least triplicates using at least three different batches of cells from different individuals. In some experiments, samples from more than three different individuals were used; ns (not significant) P40.05, *Po 0.05, **Po0.01, ***Po0.001. In figures mean ± s.e.m. are given.
